ACIU (AC Immune) Common Stock : $2.50 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Common Stock?

AC Immune's quarterly common stock increased from Jun. 2024 ($2.48 Mil) to Sep. 2024 ($2.62 Mil) but then declined from Sep. 2024 ($2.62 Mil) to Dec. 2024 ($2.50 Mil).

AC Immune's annual common stock increased from Dec. 2022 ($1.93 Mil) to Dec. 2023 ($2.42 Mil) and increased from Dec. 2023 ($2.42 Mil) to Dec. 2024 ($2.50 Mil).

AC Immune Common Stock Historical Data

The historical data trend for AC Immune's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Common Stock Chart

AC Immune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

1.73

1.95

1.93

2.42

2.50

AC Immune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															2.42	2.36	2.48	2.62	2.50

AC Immune Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

AC Immune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

IMR:Germany

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.